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This study aimed at comparing two groups of patients with Addison’s disease: A, including 180 patients described in 1991
and B, consisting of 138 patients registered since 1991. The incidence of coexisting autoimmune disorders was evaluated and
etiological factors were analyzed. Immunological and imaging studies (computed tomography in group B) were performed.
Adrenal autoantibodies were examined by an indirect immunoﬂuorescence technique in group A, and by the assay measuring
autoantibodies against steroid 21-hydroxylase in group B. Adrenal autoantibodies were revealed in 37% of patients examined by
the immunoﬂuorescence method and in 63% investigated by the modern technique. Tuberculosis was found in 52 patients in the
group A and in two patients in the group B; metastatic inﬁltrations of the adrenals in CT were detected in 16 patients. Probable
autoimmune Addison’s disease was diagnosed in 125/180 patients (69%) in the group A and in 116/138 patients (84%) in the
group B.
1.Introduction
For many years tuberculosis has been considered as the
main cause of primary adrenal insuﬃciency [1]; however,
new therapeutic methods and recent diagnostic procedures
changed our view on its etiology [2]. We have been collecting
and studying patients with adrenal insuﬃciency for over
40 years and we would like to present our experience in
this matter. Our present material consists of 318 patients
with Addison’s disease (AD) and 301 patients with the so-
called idiopathic isolated secondary adrenal insuﬃciency (a
part of this later group was described in 1998 [3] and in
2003 [4]). In 1991 we published a report on 180 patients
with AD, observed for 1 to 26 years [5]. From this time
138 new patients were referred to our department and
observed for 1 to 18 years. The aim of this study was to
compare incidence of autoimmune disorders and frequency
of tuberculosis as well as metastatic destruction of the
adrenals in these two groups of patients with AD, using more
modern techniques of diagnosis in the group observed from
1990.
2.MaterialsandMethods
2.1. Patients. 180 patients with AD, 113 women and 67 men,
aged 9 to 74 years, described in 1991 (group A) and 138
patients,97womenand41men,12to80yearsold,registered
since 1991 (group B). The patients were derived mainly
from Warsaw and a neighbouring area but a signiﬁcant
part of them was referred to our department from other,
distant clinical centers. AD was diagnosed on the basis
of clinical data [6] and the results of hormonal investiga-
tions. The most prominent clinical manifestations included
reduced strength, fatigability, anorexia, weight loss, nausea,
skin hyperpigmentation, and postural hypotension. Hyper-
kalaemia and hyponatraemia were frequent ﬁndings, more
severe in stress situations, presenting with myalgia, joint
pain, vomiting, diarrhea, and low blood pressure. The diag-
nostic hormonal criteria for including the patients into the
groups under study were low 17-hydroxycorticosteroids (17-
OHCS)urinaryexcretion(below6.0µmol/24hours,normal:
6.1–19.3µmol), low serum cortisol levels at 09.00 hours
(below 209nmol/L, normal: 209–692nmol/L), high plasma2 Autoimmune Diseases
morning ACTH concentration (more than 13.2pmol/L, in
most cases over 50pmol/L, normal: 3.3–13.2pmol/L), and
lack of signiﬁcant increase of cortisol and/or 17-OHCS
in corticotropin (Synacthen) stimulation test [5]. In two
patients with autoimmune origin of AD and six patients
with metastatic adrenal inﬁltrations or lymphoma, elevated
ACTH levels, 18.4 to 42.4pmol/L were the ﬁrst sign of
subclinical adrenal insuﬃciency.
Informed consent for the studies was obtained from all
the patients.
2.2. Methods. In clinical examination we searched for symp-
toms and signs of adrenal insuﬃciency; every patient was
also investigated for other autoimmune disorders. The prob-
ablecausesofADwereanalyzed.Theimmunologicalstudies,
performed in all patients with probable AAD, included
thyroid autoantibodies determinations: thyroglobulin (aTg)
and microsomal (aMic) antibodies assayed by haemaggluti-
nation tests (normal, <1/120) and antiperoxidase antibodies
(aTPO) by “in house” ELISA, as described previously [7]
(normal <1/80). A search for adrenal autoantibodies was
performed in 52 patients in the group A by means of an
indirectimmunoﬂuorescenttechnique[8]whileinthegroup
B a search for antibodies against steroid 21-hydroxylase (21-
OH, normal <1) and aromatic L-amino acid decarboxylase
(AADC, cut oﬀ =7) in 62 patients, as well as against steroid
17-hydroxylase (17-OH, cut oﬀ =11) and side-chain cleavage
enzyme (SCC, cut oﬀ =13) in 9 patients with associated pre-
mature ovarian failure (POF), was conducted by the method
based on the in vitro transcribed and translated protein as
describedbyEkwalletal.[9].Theuppernormallimitofeach
antibody index was established as the mean value of negative
controls plus three standard deviations and values above
this cut-oﬀ indicated the presence of adrenal autoantibodies.
Additional hormonal measurements: thyroxine, T4 or free
thyroxine, fT4, and TSH levels were measured initially by
radioimmune assays (RIA/IRMA) and during the last 10
years by chemiluminescent assay (LIA). Serum estradiol and
FSH were determined, if necessary, initially by RIA and
during last 10 years by LIA. In selected patients parathor-
mone, PTH was measured by IRMA. Various biochemical
analyses were performed, if necessary, that is, serum glucose
and HbA1c levels, calcium and phosphorus, serum and
urinary values, and alkaline phosphatase activity. Computed
tomography (CT) of the adrenals was performed in some
patients from the group B.
3. Results
Basing on the results of the clinical examination with bio-
chemical determinations, as well as immunological and
imaging investigation, we diagnosed in the group A 125
patients (87 women, F/M ratio 2.3) with probable autoim-
mune etiology (69%) and 52 (26 women, F/M ratio 1.0) with
a history of tuberculosis (29%). In two patients metastatic
inﬁltrationsandinonemanamyloidosisoftheadrenalswere
diagnosed at autopsy. Autoimmune disorders were found
in 80 patients in the group A (64% out of 125 patients
with probable autoimmune origin of AD and 44% in all the
group under study). In the group B there were 105 patients
(88 women, F/M ratio 5.0) with AD associated with some
autoimmune disorders (76% in all the group under study),
two men with tuberculosis, 16 ones (3 women, F/M ratio
0.2) with metastatic inﬁltrations of both adrenals (12%),
four with bilateral lymphoma (two women), a 53-years-old
man with bilateral adrenal cancer and 11 patients (5 women)
with idiopathic AD (8%), without any abnormalities in CT
(probably also of autoimmune origin). Characteristics of
group A and B patients are summarized in Table 1.
The imaging pattern of CT in other examined patients,
with an early stage of AAD was normal, while in two patients
with tuberculous infection adrenals were enlarged. In the
patients with AAD of long-term duration atrophic adrenals
were characteristic in the abdominal CT.
Autoimmune diseases coexisting with AD are summa-
r i z e di nT a b l e2 (the % values are calculated for the patients
with probable autoimmune AD). Thyroid abnormalities,
especially hypothyroidism and thyrotoxicosis due to Graves’
disease or Hashitoxicosis, as well as insulin dependent
diabetes mellitus (T1DM) were dominant autoimmune
disorders. In all patients with pernicious anemia atrophic
gastritis (veriﬁed by histological examinations) was found,
and in majority of them it was an early clinical ﬁnding
characteristic of this disease. Additionally, there were two
patients with chronic active hepatitis in the group A, as well
as one patient with rheumatoid arthritis, one patient with
a collagen disease and one patient with D¨ uhring’s disease in
the group B. In two patients secondary adrenal insuﬃciency
appeared after three and 18 years of AD duration with loss of
hyperpigmentation and a decrease of ACTH concentration
from 165.6 to 4.0 and from 74 to 2.2pmol/L, respectively.
Hypoparathyroidism, diagnosed as ﬁrst autoimmune
disorder in ﬁve patients, was associated with moniliasis. In
contrast, in a young male addisonian patient (brother of
a female patient with AD, T1DM, and pernicious anemia)
only moniliasis was present. Multiple autoimmune disorders
were observed in 20 patients in the group A (16%) and in 19
patients (17%) in the group B.
Thyroid autoantibodies were detected in 55% of the
patients tested in the group A and in 65% of the patients in
group B, (aMic—in 39%, aTg—in 31%, both ranging from
1/120 to 1/6480 and aTPO in 65%, ranging from 1/80 to
1/51200).
Indirect immunoﬂuorescent method revealed adrenal
autoantibodies in 19 out of 52 patients with probable
autoimmune AD (37%) in the group A. Antibodies against
21-hydroxylase were detected in 39/62 patients (63%),
ranging from 2 to >5000, most frequently in the patients
with recently diagnosed AD (in 17 patients it exceeded 20).
Antibodies against 17-hydroxylase were found in 2/9 women
with coexisting premature ovarian failure, ranging 107 and
115. Anti-SCC antibodies were revealed in the same group
in ﬁve patients (56%), ranging from 19 to 82. A signiﬁcant
level of anti-ACDD antibodies was not found in this group
of patients.
A signiﬁcant level of anti-AADC antibodies was not
found the mortality in the group A was mainly due toAutoimmune Diseases 3
Table 1: Number of patients, gender and age at onset of AD patients in the group A and B.
Etiology Gender Age at onset—years
F M median Age borders
Group A
Probable AAD 87 38 33 13–38
Tuberculosis 26 26 43 13–67
Neoplasia 0 2 48, 62
Amyloidosis 0 1 58
Group B
Etiology
Probable AAD 93 23 27 8-50
Tuberculosis 0 2 57, 78
Neoplasia 5 16 65 5–76
Table 2: Autoimmune diseases coexisting with Addison’s disease in
the group A and group B (including only the patients with probable
autoimmune disease).
Group A—total (%) Group B—total (%)
Hypothyroidism 17 (14) 47 (41)
S u b c l i n i c a l 6( 5 ) 5( 3 )
Thyrotoxicosis 15 (12) 12 (10)
Vitiligo 17 (14) 12 (10)
POF 18 (21)∗ 8( 9 ) ∗
T1DM 7 (6) 17 (15)
Pernicious anemia 4 (3) 9 (8)
Alopecia areata 3 (2) 2 (2)
Hypoparathyroidism 2 (2) 3 (3)
∗Calculated for women only.
the age-related diseases and the insuﬃciently treated tuber-
culosis. Four patients died because of malignant diseases:
colonic cancer, ovarian cancer, uterine cancer and myeloma.
In the group B, majority of patients with metastatic
destruction of adrenals as well as patients with bilateral
lymphoma died due to malignancy. Nearly all our patients
with AAD have been engaged in professional activities or
housekeeping and they have been going well at routine
control examinations. To the best of our knowledge, three
of them died due to adrenal crisis (insuﬃcient replacement
therapy in stress situation), intestinal perforation, and septic
shock.
The routine hydrocortisone doses ranged between 25
and 30mg daily, with extra doses if necessary, similarly as
in Erichsen et al. studies [10]. In the male patients with
180cm of height or more, a daily dose of 40 to 45mg
was necessary. The most frequent doses of ﬂudrocortisone
ranged from 0.05mg to 0.1mg in the morning, however in
some patients only 0.025mg has been a tolerable dosing, and
individual patients withheld this drug because of oedema.
In some patients 60 years old or older, we had to withdraw
ﬂudrocortisone because of the blood pressure increase
induced by this drug.
4. Discussion
In this paper we present a group of 318 patients with
Addison’s disease registered at our department in the last
48 years. The group of patients observed till 1990 (group
A) compared to the group registered in the last 18 years
(group B) presented a diﬀerent etiologic proﬁle. Eﬀective
chemotherapy of tuberculosis signiﬁcantly decreased the
number of patients with this type of adrenal destruction,
in our material from 29% to 1.5%. At present, only in
the developing countries tuberculous adrenalitis remains
am a j o re t i o l o g i cf a c t o r[ 11]. In contrast, detectability of
metastatic inﬁltrations of adrenal glands increased due to
modern imaging techniques from 1% in the group A to 12%
in the group B (together with bilateral adrenal lymphoma
and bilateral adrenal cancer: 15%). In some cases of this later
group we detected a subclinical AD with subtle symptoms
and elevated plasma ACTH levels. In the course of further
observation, clinical picture of AD developed in the patients
w h o s et u m o r sw e r ei n o p e r a b l e .
Autoimmune disorders accompanying AD were detected
in 80 patients in the group A (64% of 125 patients with
idiopathic AD) and in 105 patients in the group B (Table 1).
The remaining 11 patients registered recently in the group
B, without any evident autoimmune disorders, according to
Betterle et al. [2], could be classiﬁed also as idiopathic AD
of probable autoimmune etiology. Similar observations were
reported by other authors [12, 13]. Thus the incidence of
autoimmune disorders in the group B could be estimated
as 90% in 116 patients with probable autoimmune AD
and 76% in all the patients in this group. Long-term
observation of such a signiﬁcant group of patients with
AD revealed a tendency to development of some other
autoimmune disorders (mainly thyroid autoimmunity and
diabetes mellitus) in the later phases of the disease, as a sign
of a progressive autoimmune process.
Our material of nonautoimmune AD in the group B did
not diﬀer signiﬁcantly from the observations of Falorni et
al. [14]. In contrast, in the Norwegian Registry the primary
adrenal insuﬃciency was considered as almost exclusively
autoimmune disease [10].4 Autoimmune Diseases
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revealed adrenal autoantibodies in 37% out of 52 patients
in the group A. Modern assays of adrenal autoantibodies
detected autoimmunity in 43 out of 67 patients under study
(64%). This result is similar to that in Winqvist et al. study
[15].
It was characteristic that the presence of adrenal autoan-
tibodies was detected mainly in the patients with recently
diagnosed AD, while in the patients with long duration of
disease, adrenal antibodies were hardly detected or absent. In
ouropinionlackofadrenalantigenduetoacompleteadrenal
destruction in the long-term disease could be responsible
for this ﬁnding [5]. A similar suggestion was presented by
Falorni et al. [14]. It must be said however that not all
our patients were characterized for adrenal autoantibodies,
therefore we have to be cautious in opinion on that matter.
In previous studies we found high prevalence of thyroid
autoimmunity in idiopathic AD [7], which is characteristic
f o ra u t o i m m u n epo l y gl a n d u l a rs y n d r o m etype2(A P S2 )[2].
In the natural history of the thyroid autoimmune disease
the thyrotoxic patients developed hypothyroidism during
long-term observation. Thus hypothyroidism was the most
frequent,clinicallyovertautoimmunediseaseassociatedwith
AD. More than a half of the patients in the group B could
be classiﬁed as having Hashimoto’s disease, with presence
of thyroid autoantibodies (the most frequently aTPO.).
Our observations suggest an increasing tendency to thyroid
autoimmunity development in AAD [16]. No signiﬁcant
reactivitywasfoundagainstAADCthoughithasbeenshown
to correlate to vitiligo [17] which was rather frequent in
our patients. Antibodies against AADC were found in a
signiﬁcant number of Scandinavian patients [18, 19].
Diabetes mellitus and pernicious anemia were more
frequent in the group B, while premature ovarian failure
(POF) was a slightly less frequent disorder. Several forms
of POF are not of autoimmune etiology, however in a
majority of our patients with premature menopause other
autoimmune disorders have been observed. The patients
with hypoparathyroidism as the ﬁrst sign of autoimmune
disease should be classiﬁed as APS1, with diﬀerent genetic
background as compared with our other patients from the
APS2 group.
Interestingly, we observed a conversion of two patients
with AD to ACTH deﬁciency, probably due to development
of pituitary autoimmunity.
In majority of our patients the daily dose of hydrocor-
tisone, adjusted to their height and/or weight ranged 25–
30mg (divided in two or three doses). We are aware that
such dosage exceeds slightly the normal cortisol secretion
rate, but patients feel better on this dose and one cannot
exclude a possibility that such a bit higher dose could delay
development or alleviate the course of other autoimmune
disorders. Less frequently, a dose of 20mg of hydrocortisone
was prescribed, mainly in the patients with obesity or
genetically prone to obesity. Some clinical observations
suggest that patients being on 15–20mg of hydrocortisone
daily do not feel fully comfortable. We cannot exclude a
possibility that they present a hydrocortisone deﬁciency in
some “substress” situations, not included in a routine stress
deﬁnition. May be the oral hydrocortisone modiﬁed release
tablets, mimicking the physiological serum cortisol proﬁle,
will be a better therapeutic oﬀer for many AD patients [20].
A stable incidence of AD is suggested in the literature.
In our observations however, it is the secondary adrenal
insuﬃciency which became a more frequent adrenal disease,
mainly due to the improved detectability.
5. Conclusions
(1) At present, in our country, tuberculosis does not play
any signiﬁcant role in etiology of AD. (2) Detection of
metastatic lesions of adrenal glands increased evidently due
to new imaging techniques. (3) Modern methods of adrenal
antibodies determinations detected adrenal autoimmunity
in a higher number of patients with AD than indirect
immunoﬂuorescence, more frequently in patients with AD
of short duration. (4) Thyroid autoimmunity was the most
frequent autoimmune disorder accompanying AD.
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